Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Revance Therapeutics, Inc. - Common Stock (NQ: RVNC )

3.650 UNCHANGED
Last Price Updated: 4:00 PM EST, Feb 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Revance Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
The Law Offices of Frank R. Cruz Announces Investigation of Revance Therapeutics, Inc. (RVNC) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Revance Therapeutics, Inc. (RVNC) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Revance Therapeutics, Inc. (RVNC) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
Botox Innovator Revance Therapeutics Goes Private In Over $900M Deal
Crown Laboratories will acquire Revance Therapeutics for $924 million, paying $6.66 per share — a premium of 89%. 
Via Benzinga
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BTTR, RVNC, ARC, RFL on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
REVANCE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Revance Therapeutics, Inc. - RVNC
From Kahn Swick & Foti, LLC
Via Business Wire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITI, RVNC, BALY, DRQ on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
Gold Gains Over 1%; Starbucks Shares Move Higher
Via Benzinga
Why Is Revance Therapeutics (RVNC) Stock Up 86% Today?
Revance Therapeutics stock is up on Monday as RVNC investors celebrate a $924 million merger agreement with Crown Laboratories. 
Via InvestorPlace
Crude Oil Surges 2%; B. Riley Financial Shares Plunge
Via Benzinga
Exposures Fossil Fuels
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Revance Therapeutics, Inc. (Nasdaq – RVNC), Greenbrook TMS, Inc. (OTC – GBNHF), R1 RCM Inc. (Nasdaq - RCM), Enstar Group Limited (Nasdaq – ESGR)
From Brodsky & Smith LLC
Via GlobeNewswire
KE Holdings, KeyCorp, Revance Therapeutics, Starbucks And Other Big Stocks Moving Higher On Monday
Via Benzinga
RVNC Investigation: Halper Sadeh LLC Is Investigating Whether the Sale of Revance Therapeutics, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Dow Dips 150 Points; Monday.com Posts Upbeat Earnings
Via Benzinga
Topics Stocks
Exposures US Equities
RVNC Stock Earnings: Revance Therapeutics Beats EPS, Misses Revenue for Q2 2024
RVNC stock results show that Revance Therapeutics beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024. 
Via InvestorPlace
Revance Reports Second Quarter 2024 Financial Results, Provides Corporate Update
From Revance Therapeutics, Inc.
Via Business Wire
Revance to Release Second Quarter 2024 Financial Results on Thursday, August 8, 2024
From Revance Therapeutics, Inc.
Via Business Wire
AbbVie Could Soar 24%, According to a Wall Street Analyst. Is the High-Yield Dividend Stock a Buy Now?
The big pharma company's top drug is losing ground, but its dividend keeps rising. 
Via The Motley Fool
Stocks to Buy: 3 Breakout Stars to Transform Your Portfolio
Although breakout stocks present high risks, the underlying lack of predictability provides fuel for tremendous upside. 
Via InvestorPlace
Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Revance Therapeutics, Inc.
Via Business Wire
Revance to Participate in Upcoming Investor Conferences
From Revance Therapeutics, Inc.
Via Business Wire
The 100%+ Club: Piper Sandler’s 3 Top Picks for Triple-Digit Gains
Biotechs can see triple-digit returns or dramatic losses but these Piper Sandler stocks have the potential to achieve them. 
Via InvestorPlace
3 Underappreciated Stocks That Could 10x in 10 Years
10x stocks are the holy grail of capital investing. So, here are three companies that have the potential to cross that line. 
Via InvestorPlace
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Why Diodes Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
These Analysts Lower Their Forecasts On Revance Therapeutics After Q1 Results
Via Benzinga
RVNC Stock Earnings: Revance Therapeutics Beats EPS, Misses Revenue for Q1 2024
RVNC stock results show that Revance Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Revance Reports First Quarter 2024 Financial Results, Provides Corporate Update
From Revance Therapeutics, Inc.
Via Business Wire
Revance Expands into the U.S. Therapeutics Market with the Launch of DAXXIFY® for the Treatment of Cervical Dystonia
From Revance Therapeutics, Inc.
Via Business Wire
Revance to Release First Quarter 2024 Financial Results on Thursday, May 9, 2024
From Revance Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.